Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.
All articles by Laura Healy
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Pano/GBM Plus ASCT Deemed Safe and Effective in High-Risk or Rel/Ref MM
Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.
Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
Bivalent COVID-19 Vaccine May Not Protect Cancer Patients From Current Variants
Pfizer-BioNTech’s bivalent COVID-19 vaccine may not protect cancer patients from the most common omicron subvariant in circulation now, a study suggests.
“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Patients With Double-Hit Multiple Myeloma Have Inferior Outcomes After Transplant
The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...